Propeller Health acquired by ResMed for $225M

FierceHealthcare | December 03, 2018

A Wisconsin-based startup that makes digital inhalers has been purchased by medical device giant ResMed for $225 million. Propeller Health, which bills itself as the “leading digital therapeutics company” created a digital inhaler to help patients with chronic obstructive pulmonary disease (COPD), a disease that impacts 16 million Americans. ResMed CEO Mick Farrell called the purchase a “significant step for ResMed towards becoming the global leader in digital health for COPD.” ResMed has manufactured more than 6 million cloud-connected remote monitoring devices, with a focus on sleep apnea and respiratory illnesses.

Spotlight

Health Care Purchaser Getting High-Value Care

Spotlight

Health Care Purchaser Getting High-Value Care

Related News

HEALTHTECH SECURITY,HEALTHCARE ANALYTICS

Carle Health Partners with Health Catalyst to Achieve Data-Informed Improvement

Health Catalyst | December 06, 2022

Health Catalyst, Inc. a leading provider of data and analytics technology and services to healthcare organizations announced an expansive, multi-year contract with Carle Health an integrated health system based in Urbana, Illinois that includes five hospitals, multi-specialty physician group practices with more than 1,000 doctors and advanced practice providers, and Health Alliance Medical Plans—deepening its relationship with Health Catalyst to further advance Carle's innovative analytics capabilities system-wide. "Carle Health is excited to announce this novel partnership with Health Catalyst. When combined with our own clinical expertise, Health Catalyst will help us transform the way we use data to support organizational decisions and improve patient outcomes. As a transformative health care system, it's important that we lay the groundwork to ensure we're able to provide the right solutions that blend data, analytics, and medical expertise to optimize the quality of care we provide for everyone who depend on us." Carle Health Chief Operating Officer, Matthew Kolb Strengthening the existing relationship between Health Catalyst and Carle, this five-year agreement will include an all-access technology subscription, plus tech-enabled managed services in the areas of analytics, data management, reporting, and project management. Beginning in January 2023, Carle Health Clinical and Business Intelligence team members will transfer employment to Health Catalyst, where they will have the opportunity to grow professionally within Health Catalyst's enhanced environment of data literacy and technology resources. As Health Catalyst employees, transitioned team members will constitute a specialized, expert team that will continue to provide analytics support and innovation to the Carle Health system. "We're grateful to have been a partner with such a high-performing health system as Carle these past two years, contributing to its data-driven healthcare transformation efforts," said Dan Burton, CEO of Health Catalyst. "We are honored to have been chosen by Carle to continue supporting them in bringing more technology to complement and strengthen their healthcare services. Carle Health will realize greater data-informed opportunities through this partnership and we look forward to the improvements they will continue to make for their patients and the larger community." Health Catalyst is focused on deepening and strengthening existing partnerships to help clients achieve massive, measurable healthcare improvement. Health Catalyst and Carle first entered a partnership in 2020, which enabled Carle to leverage Health Catalyst's open, scalable data platform to gain access to data and analytics solutions to measure quality and cost of care, allowing for increased and efficient sharing of analytics, and provide a comparative analytics platform to help increase learnings about costs, outcomes, and trending best practices. Upon signing this contract expansion through 2028, Carle becomes one of Health Catalyst's largest enterprise and tech-enabled outsourcing clients, reaffirming their commitment to analytics technology that improves the quality of care delivered to patients and health plan members. Health Catalyst's expanded relationship with Carle underscores the company's compelling value proposition, significant continued commercial momentum, and the trust Health Catalyst's clients place in the company. This expansion is included in the financial guidance that Health Catalyst most recently provided during its third quarter 2022 earnings. About Health Catalyst Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Its more than 500 clients leverage the cloud-based data platform or its other software applications—powered by data from over 100 million patient records and encompassing trillions of facts—as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future in which all healthcare decisions are data informed. About Carle Health Carle Health combines clinical care, health insurance, research and academics in a way that solves real-world problems today with an eye toward the future. Supported by a deep philanthropic spirit, Carle is dedicated to doing what it takes to make life better for as many as possible. Its mission is to be your trusted partner in all healthcare decisions. Based in Urbana, IL, Carle Health is an integrated system of healthcare services, which includes a five-hospital system, multi-specialty physician groups, as well as the Carle Illinois College of Medicine and the Stephens Family Clinical Research Institute.

Read More

FUTURE OF HEALTHCARE

BioIntelliSense Joins Polaris Dawn Mission to Advance Understanding of Human Health in Space

BIOINTELLISENSE | November 15, 2022

BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, today announced its partnership with the Translational Research Institute for Space Health (TRISH) to further understanding of human health in space. The BioButton® medical grade wearable device will be used for commercial spaceflight research programs and notably during the upcoming five-day Polaris Dawn mission. This historic mission will be flown by SpaceX and is scheduled to launch after March 2023. Medical and scientific research on human health in space promotes the advancement of translational technologies by adapting known technology for space applications, and by using space-based insights to improve healthcare at home. “BioIntelliSense has proudly gained industry recognition for its innovative and comprehensive portfolio of continuous multi-parameter monitoring solutions for application in the acute care environment, at home settings and now, in the next frontier of space, As a lifelong space exploration enthusiast, it is a tremendous honor to be working with TRISH on health research that can benefit astronauts and crews during commercial space flight and for the BioButton devices to be part of the upcoming Polaris Dawn mission.” -James Mault, MD, founder and CEO of BioIntelliSense The BioButton multi-parameter device is designed to be worn on the upper left chest and will passively capture trending physiologic and movement data from the Polaris Dawn crew during its milestone mission. The future of healthcare is here. Today, the BioIntelliSense Data-as-a-Service (DaaS) platform and clinical intelligence solution is commercially available and rapidly adopted by acute and post-acute providers in the U.S. along with select international markets. TRISH is proud to partner with innovative healthcare technology leaders like BioIntelliSense as we further our understanding of human health in space, Our EXPAND (Enhancing eXploration and ANalog Definition) commercial spaceflight health research platform provides unique opportunities to rapidly test technologies in orbit, as well as collect new datapoints on the health impact of spaceflight for a wider, more diverse population,said James Hury, TRISH Chief Innovation Officer and Deputy Director. BioIntelliSense (Booth #5025) and TRISH (Space Health Pavilion #2636) will be showcasing the BioButton wearable device and clinical intelligence solution at the premier HLTH 2022 conference November 13 – 16 in Las Vegas, NV. ABOUT BIOINTELLISENSE BioIntelliSense is ushering in a new era of continuous health monitoring and clinical intelligence for remote patient monitoring (RPM). Its medical-grade Data-as-a-Service (DaaS) platform seamlessly captures multi-parameter vital signs, physiological biometrics and symptomatic events through an effortless patient experience. The medical-grade BioButton® wearable device makes remote monitoring and early detection simple. Through the platform’s advanced analytics, clinicians have access to high-resolution patient trending and reporting to enable medical grade remote care from in-hospital to home. ABOUT TRANSLATIONAL RESEARCH INSTITUTE for SPACE HEALTH (TRISH) Led by Baylor College of Medicine’s Center for Space Medicine, TRISH is a consortium that includes partners Caltech and MIT. NASA recently awarded the Institute a six-year extension to further its work by delivering disruptive solutions to mitigate biomedical risks for human exploration while advancing terrestrial health technologies.

Read More

HEALTH TECHNOLOGY, MEDICAL DEVICES

Signify Health and Prospect Medical Holdings Team Up to Provide Top-notch Care

Signify Health | January 12, 2023

Signify Health, a top healthcare platform that uses advanced analytics, technology, and nationwide healthcare networks, announced a new partnership with Prospect Medical Holdings, Inc., a growing healthcare services company on January 11, 2023. The collaboration will help create and run value-based payment programs for superior care. To improve care transformation, manage risk, and provide high-quality, coordinated patient care for its traditional Medicare fee-for-service patients, Prospect's Waterbury HEALTH and Eastern Connecticut Health Network (ECHN) facilities and their affiliated provider network in Connecticut will join a Signify-enabled accountable care organization (ACO) in 2023 as part of the Medicare Shared Savings Program (MSSP). Signify Health will assist Prospect facilities in managing their MSSP ACO risk, lowering costs, and increasing quality incentives by providing data-driven, tailored population health roadmaps. Patients who seek treatment at Prospect's hospitals, which provide care to underprivileged and diverse populations across the state, will benefit from the strategic partnership. EJay Lockwood, Vice President, Connecticut Coordinated Care at Prospect Medical Holdings stated, "Every healthcare market is different to a certain extent, but we were impressed by Signify's experience that has spanned so many markets and has managed to 'stay local' while simultaneously honing their approach to delivering on the core competencies that any successful ACO needs to have." (Source: Business Wire) Tim Gronniger, Chief of Value-based Care Solutions, Signify Health, shared, "Prospect's Connecticut teams serve patients living in economically disadvantaged areas who also have been medically underserved. Through our work together, Prospect's Medicare patients will receive needed increased access to preventative and in-home services that will help improve their health outcomes, while creating a better overall experience for both patients and their care teams." (Source: Business Wire) About Signify Health At Signify Health, a renowned healthcare platform, cutting-edge analytics, technology, and national healthcare provider networks enable value-based payment options. Health plans and organizations use the company's technologies to assess risk and develop ways to enhance patient outcomes, coordination, and cost. Its platform coordinates clinical, social, and behavioral treatments. Signify Health meets customers' needs, reduces costs, and brings care closer to home.

Read More